Human medicines European public assessment report (EPAR): Koselugo, selumetinib, Date of authorisation: 17/06/2021, Revision: 9, Status: Authorised
Koselugo is a medicine used to treat plexiform neurofibromas, benign (non-cancerous) tumours along the nerves, when they cause symptoms and cannot be removed by surgery in adults a…
该文章暂未提取到完整正文,已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
Produits lies a cet article
Ces produits ont ete automatiquement associes au titre, au resume et au contenu de l article.
Questions frequentes
Which products are related to this article?
The system matched these relevant products from the article content: SEMEDX Selumetinib Lucius Smectinib Koselugo – Acheter en ligne SEMEDX Selumetinib DABRADX Dabrafenib 75 mg.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.